A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
Learn more about:
Related Clinical Trial
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Sporadic Inclusion Body Myositis Natural History Study
Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells
Phase III Trial of Sirolimus in IBM
A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)
Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis
Natural History in CCFDN and IBM Syndromes
Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Study of Pioglitazone in Sporadic Inclusion Body Myositis
Lithium in Inclusion Body Myositis (IBM)
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Study of Arimoclomol in Inclusion Body Myositis (IBM)
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Blood-flow Restricted Exercise in Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis – Open Label Extension Trial
Molecular Profile of the Evolution of Inclusion Body Myositis
Natalizumab in Inclusion Body Myositis (IBM)
Arimoclomol in Sporadic Inclusion Body Myositis